Minal R. Patel

Minal R. Patel

Auto-generated profile, based on publicly available information

Minal R. Patel

University of Michigan, Ann Arbor, MI, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in Medical Care
Verified
Journal Article
Closed access
MPMinal R. Patel
Minal R. Patel
JPJohn D. Piette
John D. Piette
KRKenneth Resnicow
Kenneth Resnicow
TKTheresa Kowalski-Dobson
Theresa Kowalski-Dobson
MHMichele Md Heisler
Michele Md Heisler
Background: Cost-related nonadherence (CRN) is prevalent among individuals with diabetes and can have significant negative health consequences. We examined health-related and non–health-related pressures and the use of cost-reducing strategies among the US adult population with and without diabetes that may impact CRN. Methods: Data from the 2013 wave of National Health Interview Survey (n=34,557) were used to identify the independent impact of perceived financial stress, financial insecurity with health care, food insecurity, and cost-reducing strategies on CRN. Results: Overall, 11% (n=4158) of adults reported diabetes; 14% with diabetes reported CRN, compared with 7% without diabetes. Greater perceived financial stress [prevalence ratio (PR)=1.07; 95% confidence interval (CI), 1.05–1.09], financial insecurity with health care (PR=1.6; 95% CI, 1.5–1.67), and food insecurity (PR=1.30; 95% CI, 1.2–1.4) were all associated with a greater likelihood of CRN. Asking the doctor for a lower cost medication was associated with a lower likelihood of CRN (PR=0.2; 95% CI, 0.2–0.3), and 27% with CRN reported this. Other cost-reducing behavioral strategies (using alternative therapies, buying prescriptions overseas) were associated with a greater likelihood of CRN. Conclusions: Half of the adults with diabetes perceived financial stress, and one fifth reported financial insecurity with health care and food insecurity. Talking to a health care provider about low-cost options may be protective against CRN in some situations. Improving screening and communication to identify CRN and increase transparency of low-cost options patients are pursuing may help safeguard from the health consequences of cutting back on treatment.

1 February 2008 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
TDTerence M. Davidson
Terence M. Davidson
MPMinal R. Patel
Minal R. Patel

1 August 2008 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
GBGregory C. Barkdull
Gregory C. Barkdull
CKChad A. Kohl
Chad A. Kohl
MPMinal Patel
Minal Patel
TDTerence M. Davidson
Terence M. Davidson

1 September 2022 in Diabetes Care
Verified
Journal Article
Open access
PDF file
MPMinal R. Patel
Minal R. Patel
GZGuanghao Zhang
Guanghao Zhang
MHMichele Heisler
Michele Heisler
PSPeter X.K. Song
Peter X.K. Song
JPJohn D. Piette
John D. Piette
KRKenneth Resnicow
Kenneth Resnicow
OBJECTIVE: The Comprehensive Score for Financial Toxicity–Functional Assessment of Chronic Illness Therapy (COST-FACIT) is a validated instrument measuring financial distress among people with cancer. The reliability and construct validity of the 11-item COST-FACIT were examined in adults with diabetes and high A1C. RESEARCH DESIGN AND METHODS: We examined the factor structure (exploratory factor analysis), internal consistency reliability (Cronbach α), floor/ceiling effects, known-groups validity, and predictive validity among a sample of 600 adults with diabetes and high A1C. RESULTS: COST-FACIT demonstrated a two-factor structure with high internal consistency: general financial situation (7-items, α = 0.86) and impact of illness on financial situation (4-items, α = 0.73). The measure demonstrated a ceiling effect for 2% of participants and floor effects for 7%. Worse financial toxicity scores were observed among adults who were women, were below the poverty line, had government-sponsored health insurance, were middle-aged, were not in the workforce, and had less educational attainment (P < 0.01). Worse financial toxicity was observed for those engaging in cost coping behaviors, such as taking less or skipping medicines, delaying care, borrowing money, “maxing out” the limit on credit cards, and not paying bills (P < 0.01). In regression models for the full measure and its two factors, worse financial toxicity was correlated with higher A1C (P < 0.01), higher levels of diabetes distress (P < 0.01), more chronic conditions (P < 0.01), and more depressive symptoms (P < 0.01). CONCLUSIONS: Findings support both the reliability and validity of the COST-FACIT tool among adults with diabetes and high A1C levels. More research is needed to support the use of the COST-FACIT tool as a clinically relevant patient-centered instrument for diabetes care.

1 November 2017 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
PPPooja O. Patel
Pooja O. Patel
MPMinal R. Patel
Minal R. Patel
ABAlan P. Baptist
Alan P. Baptist

1 December 2018 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
MPMinal R. Patel
Minal R. Patel
VPValerie G. Press
Valerie G. Press
LGLynn B. Gerald
Lynn B. Gerald
TBTeresa Barnes
Teresa Barnes
KBKathryn Blake
Kathryn Blake
JGJoe K. Gerald
Joe K. Gerald
Background: Mounting evidence indicates that out-of-pocket costs for prescription medications, particularly among low- and middle-income patients with chronic diseases, are imposing financial burden, reducing medication adherence, and worsening health outcomes. This problem is exacerbated by a paucity of generic alternatives for prevalent lung diseases, such as asthma and chronic obstructive pulmonary disease, as well as high-cost medicines for rare diseases, such as cystic fibrosis. Affordability and access challenges are especially salient in the United States, as citizens of many other countries pay lower prices for and have greater access to prescription medications. Methods: The American Thoracic Society convened a multidisciplinary committee comprising experts in health policy pharmacoeconomics, behavioral sciences, and clinical care, along with individuals providing industry and patient perspectives. The report and its recommendation were iteratively developed over a year of in-person, telephonic, and electronic deliberation. Results: The committee unanimously recommended the establishment of a publicly funded, politically independent, impartial entity to systematically draft evidence-based pharmaceutical policy recommendations. The goal of this entity would be to generate evidence and action steps to ensure people have equitable and affordable access to prescription medications, to maximize the value of public and private pharmaceutical expenditures on health, to support novel drug development within a market-based economy, and to preserve clinician and patient choice regarding personalized treatment. An immediate priority is to examine the evidence and make recommendations regarding the need to have essential medicines with established clinical benefit from each drug class in all Tier 1 formularies and propose recommendations to reduce barriers to timely generic drug availability. Conclusions: By making explicit, evidence-based recommendations, the entity can support the establishment of coherent national policies that expand access to affordable medications, improve the health of patients with chronic disease, and optimize the use of public and private resources.